Scarica l'app Stockscreener
1.80
4.65%
0.08
Precedente Chiudi:
$1.72
Aprire:
$1.91
Volume 24 ore:
4.78M
Relative Volume:
1.62
Capitalizzazione di mercato:
$8.07M
Reddito:
$72,100
Utile/perdita netta:
$-3.60M
Rapporto P/E:
-1.5126
EPS:
-1.19
Flusso di cassa netto:
$-3.37M
1 W Prestazione:
+65.14%
1M Prestazione:
+115.54%
6M Prestazione:
+78.22%
1 anno Prestazione:
+24.45%
Intervallo 1D:
$1.80
$2.1608
Intervallo di 1 settimana:
$1.51
$3.3699
Portata 52W:
$0.77
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Nome
Silo Pharma Inc
Settore
Industria
Telefono
(718) 400-9031
Indirizzo
677 N. WASHINGTON BLVD, SARASOTA
Confronta SILO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2275 | 480.10M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.53 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.65 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.58 | 111.10M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
3.52 | 45.79M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Borsa (SILO) Ultime notizie
Silo Pharma awarded U.S. patent for PTSD treatment - Yahoo Finance
Silo Pharma secures patent for PTSD intranasal treatment By Investing.com - Investing.com Nigeria
Silo Pharma shares soar on patent allowance news By Investing.com - Investing.com South Africa
Silo Pharma shares soar on patent allowance news - Investing.com
Silo Pharma secures patent for PTSD intranasal treatment - Investing.com
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial - The Manila Times
Silo Pharma Secures Key Patent Protection for PTSD Treatment SPC-15, Strengthens IP Portfolio - StockTitan
SILO Pharma flies high on impending patent for intranasal PTSD drug - Mugglehead
Silo Pharma progresses with PTSD and pain treatments - Investing.com
Silo Pharma Issues Letter to Shareholders Detailing - GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - Yahoo Finance UK
Silo Pharma initiates pharmacokinetic, tolerability study for SP-26 - Yahoo Finance
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - The Manila Times
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for Sp-26 Targeting Chronic Pain and Fibromyalgia - Marketscreener.com
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain - The Bakersfield Californian
Silo Pharma Launches Groundbreaking Ketamine Implant Study for Chronic Pain Treatment - StockTitan
Silo Pharma partners with Kymanox to develop ketamine implant - MSN
Why Is Silo Pharma Stock Gaining Today? - Benzinga
Silo Pharma advances ketamine implant for chronic pain By Investing.com - Investing.com UK
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewswire
Silo Pharma Partners with Kymanox to Develop Novel Ketamine Implant Device | SILO Stock News - StockTitan
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Silo Pharma stock hits 52-week low at $0.83 amid market challenges - Investing.com Canada
Silo Pharma stock hits 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock - Investing.com
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock By Investing.com - Investing.com Canada
Silo Pharma Inc. Share PriceSILO, RNS News, Articles, Quotes, & Charts (NASDAQ: SILO) - Proactive Investors Australia
Silo Pharma reports promising preclinical results in treating severe stress-related disorders - Proactive Investors UK
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - The Manila Times
Silo Pharma reports progress in PTSD treatment study - Investing.com
Silo Pharma reports progress in PTSD treatment study By Investing.com - Investing.com UK
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023) - Yahoo Finance
SILOSilo Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewswire
Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - Marketscreener.com
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Japan Ice Bank Silo Market By Application - Third Eye News
SILO Pharma (NASDAQ:SILO) Stock Quotes, Forecast and News Summary - Benzinga
Exclusive Come Home Trailer Previews Horror Thriller Movie Featuring Silo Stars - ComingSoon.net
Egypt: General Company for Silos’s profits rise 45.6% YoY in FY2023/24 - ZAWYA
Silvis Materials Awarded $1 Million NSF SBIR Phase II Grant to Reduce Emissions in Packaging and Building - EIN News
FDA Grants Accelerated Approval to Gilead’s Livdelzi for Primary Biliary Cholangitis - The Healthcare Technology Report.
Serpin Pharma and Uniklinikum Erlangen Team Up for a Clinical Trial to Prevent Acute Kidney Injury - EIN News
New Silo Season 2 Character Is Very Closely Copying An Iconic 2000s TV Show - Screen Rant
Roli Mosimann (Swans / Wiseblood / The The) has died - Brooklyn Vegan
SosMula Finally Delivers "SLEEZ RELIGION" - HotNewHipHop
Silo Pharma Inc Azioni (SILO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Silo Pharma Inc Azioni (SILO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
| Weisblum Eric | CEO and President |
Jun 12 '24 |
Buy |
1.11 |
4,438 |
4,926 |
180,432 |
| Weisblum Eric | CEO and President |
Jun 11 '24 |
Buy |
1.08 |
562 |
607 |
175,994 |
| Weisblum Eric | CEO and President |
Apr 04 '24 |
Buy |
1.96 |
600 |
1,176 |
175,032 |
| Weisblum Eric | CEO and President |
Apr 05 '24 |
Buy |
2.03 |
400 |
812 |
175,432 |
| Weisblum Eric | CEO and President |
Mar 28 '24 |
Buy |
1.94 |
3,408 |
6,612 |
173,332 |
| Weisblum Eric | CEO and President |
Apr 01 '24 |
Buy |
1.91 |
1,100 |
2,101 |
174,432 |
0.13%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):